Ivermectin licensing in the UK

Why a much-needed scabies medicine is being kept back

A medicine that could control outbreaks of scabies in the UK is unlicensed and only available through specialist importers, researchers at Brighton and Sussex Medical School (BSMS) have found.

Photo

Image source: Eric Erbe; digital colorization by Chris Pooley (USDA, ARS, EMU).[2], Rust Mite, Aceria anthocoptes, marked as public domain, details at Wikimedia Commons

In July 2019, the World Health Organization (WHO) updated its model list of essential medicines to include oral ivermectin for scabies-related infections. This recommendation follows the 2017 WHO categorisation of scabies as a neglected tropical disease. In the UK, scabies outbreaks are a substantial public health burden in care homes for older people. Yet this medicine, endorsed as essential and safe by WHO, remains unlicensed for scabies treatment in the UK. 

Standard treatment consists of topical acaricides, applied over the whole body the same day to all residents and staff, left on usually overnight before showering, and repeated seven days later. This process is labour intensive and can be distressing, especially for residents with dementia who might not understand why it is happening.

If you are an elderly person in a care home in Surrey you are unlikely to get [ivermectin]. This needs to change

Jo Middleton

Researchers at BSMS published a letter in The Lancet to address this. Jo Middleton, first author on the letter and Research Fellow, Department of Primary Care and Public Health and the NIHR Global Health Unit on Neglected Tropical Diseases at BSMS, says: "The World Health Organization has declared ivermectin an essential medicine for scabies, and it is increasingly used worldwide. For example, we have a PhD student investigating its impact on scabies in remote areas of Ethiopia. Yet in the UK it is still unlicensed, so if you are an elderly person in a care home in Surrey you are unlikely to get it. This needs to change." 

Professor Jackie Cassell, Deputy Dean at BSMS, adds: “In our research programme on scabies in care homes, we have seen the considerable distress experienced by frail confused older people who undergo whole body treatments with lotions for scabies. An oral treatment option is essential to reduce the impact of scabies and its treatment in these very vulnerable people”.


Source: Brighton and Sussex Medical School (BSMS)

20.12.2019

More on the subject:
Read all latest stories

Related articles

Photo

Several methods for early diagnosis of Alzheimer's disease developed by European scientists

PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer's disease. Diagnosis requires a holistic view of the patient…

Photo

Contrast-induced nephropathy

Contrast induced nephropathy (CIN) is widely recognised as a potentially serious complication of contrast media use -- a risk that increases with a patient’s age and decreased renal function.

One in seven hospital patients suffer adverse drug reactions

UK - Following a six-month study of 3,000 hospital patients in 12 wards in Merseyside, researchers at Liverpool University found that one in seven had suffered adverse drug reactions.